Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-mutated CALR immune therapeutic
- Development stage
- Unknown
- Lead developer
- Janssen Research & Development
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
The anti-mutated CALR immune therapeutic is a biological agent, specifically a monoclonal antibody, developed by MyeloPro in collaboration with Janssen. It is designed to selectively target the C-terminal neoepitope of mutated calreticulin (CALR), a driver mutation found in a significant proportion of patients with myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET) and primary myelofibrosis (PMF). In these diseases, the CALR mutation creates a novel protein sequence that constitutively binds to and activates the thrombopoietin receptor (MPL), leading to uncontrolled cell proliferation. This therapeutic binds to the mutant CALR protein on the cell surface to inhibit oncogenic signaling and induce immune-mediated clearance of the malignant clones. It is currently being investigated in Phase 1 clinical trials to evaluate its safety and efficacy in patients with CALR-mutant MPNs.
- Other names
- anti-mutated CALR antibodyMyeloPro anti-CALR therapeuticmutated calreticulin immune therapeutic
02
Targets
CALR mutant (Calreticulin Mutant Protein)TPOR (Thrombopoietin receptor)
Beyond the preview
Go deeper on anti-mutated CALR immune therapeutic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-mutated CALR immune therapeutic.